Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $14.17

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $14.17.

A number of brokerages have recently commented on BCRX. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Barclays lifted their price objective on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. JMP Securities lifted their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. Finally, StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently made changes to their positions in BCRX. CWM LLC lifted its stake in BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,772 shares in the last quarter. Signaturefd LLC lifted its position in BioCryst Pharmaceuticals by 560.5% during the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after buying an additional 5,599 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at about $63,000. Seven Eight Capital LP purchased a new stake in shares of BioCryst Pharmaceuticals in the first quarter valued at about $57,000. Finally, Natixis increased its position in BioCryst Pharmaceuticals by 400.6% during the first quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 9,350 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $7.49 on Tuesday. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $8.88. The company has a market capitalization of $1.55 billion, a PE ratio of -7.00 and a beta of 1.88. The company has a fifty day moving average of $7.81 and a 200 day moving average of $6.65.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.11. The company had revenue of $109.30 million during the quarter, compared to analyst estimates of $98.30 million. The business’s quarterly revenue was up 34.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.24) EPS. Research analysts expect that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.